

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549  
 FORM D

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity

<p><b>CIK (Filer ID Number)</b>  <a href="#">0001292519</a></p> <p><b>Name of Issuer</b>                  INVIVO THERAPEUTICS HOLDINGS CORP.</p> <p><b>Jurisdiction of Incorporation/Organization</b>                  NEVADA</p> <p><b>Year of Incorporation/Organization</b>                  X Over Five Years Ago                  Within Last Five Years (Specify Year)                  Yet to Be Formed</p>	<p><b>Previous Names</b> None</p> <p>Design Source, Inc.</p>	<p><b>Entity Type</b></p> <p>X Corporation                  Limited Partnership                  Limited Liability Company                  General Partnership                  Business Trust                  Other (Specify)</p>
--	--	--

2. Principal Place of Business and Contact Information

<b>Name of Issuer</b>			
INVIVO THERAPEUTICS HOLDINGS CORP.			
<b>Street Address 1</b>		<b>Street Address 2</b>	
ONE KENDALL SQUARE		Suite B14402	
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	<b>Phone Number of Issuer</b>
CAMBRIDGE	MASSACHUSETTS	02139	617-863-5524

3. Related Persons

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>
Toselli	Richard	
<b>Street Address 1</b>	<b>Street Address 2</b>	
One Kendall Square	Suite B14402	
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b> X Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>
Christopher	Richard	
<b>Street Address 1</b>	<b>Street Address 2</b>	
One Kendall Square	Suite B14402	
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b> X Executive Officer Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Merrifield	C.	Ann
Street Address 1	Street Address 2	
One Kendall Square	Suite B14402	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Marshak	Daniel	
Street Address 1	Street Address 2	
One Kendall Square	Suite B14402	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Morrison	Christina	
Street Address 1	Street Address 2	
One Kendall Square	Suite B14402	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Roberts	Richard	
Street Address 1	Street Address 2	
One Kendall Square	Suite B14402	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Rosenthal	Robert	
Street Address 1	Street Address 2	
One Kendall Square	Suite B14402	
City	State/Province/Country	ZIP/PostalCode
Cambridge	MASSACHUSETTS	02139
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

#### 4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology

Insurance  
Investing  
Investment Banking  
Pooled Investment Fund  
Is the issuer registered as an investment company under the Investment Company Act of 1940?  
Yes                      No  
Other Banking & Financial Services  
Business Services  
Energy  
Coal Mining  
Electric Utilities  
Energy Conservation  
Environmental Services  
Oil & Gas  
Other Energy

Hospitals & Physicians  
Pharmaceuticals  
Other Health Care  
Manufacturing  
Real Estate  
Commercial  
Construction  
REITS & Finance  
Residential  
Other Real Estate

Computers  
Telecommunications  
Other Technology  
Travel  
Airlines & Airports  
Lodging & Conventions  
Tourism & Travel Services  
Other Travel  
Other

5. Issuer Size

<b>Revenue Range</b>	<b>OR</b>	<b>Aggregate Net Asset Value Range</b>
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
X Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)
Rule 506(c)	Section 3(c)(6)	Section 3(c)(14)
Securities Act Section 4(a)(5)	Section 3(c)(7)	

7. Type of Filing

X New Notice    Date of First Sale 2020-04-17    First Sale Yet to Occur  
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?    Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$ 0 USD

12. Sales Compensation

Recipient	Recipient CRD Number	None
H.C. Wainwright & Co., LLC	375	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number	X None
None	None	
	<b>Street Address 1</b>	<b>Street Address 2</b>
430 Park Avenue	4th Floor	
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10022
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	X All States	Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$ 3,022,576 USD or Indefinite  
 Total Amount Sold \$ 3,022,576 USD  
 Total Remaining to be Sold \$ 0 USD or Indefinite

Clarification of Response (if Necessary):

Private Placement of (i) warrants to purchase 1,715,240 shares of common stock at a purchase price of \$1.62 per share and (ii) warrants to purchase 111,491 shares of common stock at a purchase price of \$2.1875 per share

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. 8

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ 255,152 USD Estimate  
 Finders' Fees \$ 0 USD Estimate

Clarification of Response (if Necessary):

## 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0 USD    Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
INVIVO THERAPEUTICS HOLDINGS CORP.	/s/ Richard Christopher	Richard Christopher	Chief Financial Officer	2020-04-28

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.